Outcomes of COVID-19 in patients with CLL: a multicenter international experienceAnthony R. Mato, José‐Ángel Hernández‐Rivas, Manali Kamdar et al.|Blood|2020Cited by 318
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual DiseaseTalha Munir, Peter Hillmen, David A. Cairns et al.|New England Journal of Medicine|2023Cited by 155
Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post‐<scp>BCR</scp>inhibitor setting: a<scp>UK</scp>wide analysisToby A. Eyre, Amy A. Kirkwood, Satyen H. Gohil et al.|British Journal of Haematology|2019Cited by 79
COVID-19 in patients with CLL: improved survival outcomes and update on management strategiesLindsey E. Roeker, Sigrid S. Skånland, Toby A. Eyre et al.|Blood|2021Cited by 70
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic LeukemiaTalha Munir, Peter Hillmen, Sean Girvan et al.|New England Journal of Medicine|2025Cited by 26